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ABSTRACT 
Purpose - To examine time trends of management and mortality of acute coronary 
syndrome patients with associated diabetes mellitus. 
Methods - We analyzed data from 5 nationwide registries established between 2001 and 
2014, including consecutive acute coronary syndrome patients admitted to the Italian 
Intensive Cardiac Care Units. 
Results – Out of 28,225 participants, 8,521 (30.2%) had diabetes: as compared to patients 
without diabetes, they were older and had significantly higher rates of prior myocardial 
infarction and comorbidities (all p<0.0001). Prevalence of diabetes and comorbidities 
increased over time (p for trend <0.0001).  Cardiogenic shock rates were higher in patients 
with diabetes, as compared to those without diabetes (7.8% vs 2.8%, p<0.0001), and 
decreased significantly over time only in patients without diabetes (p=0.007). 
Revascularization rates increased over time both in patients with and without diabetes (both p 
for trend <0.0001), though with persistingly lower rates in patients with diabetes. All-cause 
in-hospital mortality was higher in patients with diabetes (5.4 vs. 2.5%, respectively, 
p<0.0001) and decreased more consistently in patients without diabetes (p for trend=0.007 
and<0.0001, respectively). At multivariable analysis, diabetes remains an independent 
predictor of both cardiogenic shock [OR 2.03, 95% C.I. 1.77-2.32, p<.0001]   and mortality 
[OR: 1.95; 95% CI: 1.69–2.26; p < 0.0001]. 
Conclusions – Despite significant mortality reductions observed over 15 years in acute 
coronary syndromes, patients with diabetes continue to show 3-fold higher rates of 
cardiogenic shock and lower revascularization rates as compared to patients without 
diabetes. These findings may explain the persistingly higher mortality of patients with 
diabetes and acute coronary syndromes.   
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Diabetes mellitus is a major cardiovascular risk factor leading to early death and higher 
hospitalization and complications rates. Most evidence showing an increased mortality risk 
associated with diabetes in acute coronary syndromes stems from randomized clinical trials 
and from registries of non-consecutively enrolled patients
1
, thus leaving a relative paucity of 
data on the actual daily practice. Moreover, it has not been clearly described whether the 
progressive increase of early revascularization across the spectrum of acute coronary 
syndromes observed in recent years has reduced the mortality gap between patients with and 
without diabetes.    
Over the last two decades, the Italian Association of Hospital Cardiology (ANMCO) has 
established a series of prospective registries of consecutive patients with acute coronary 
syndromes admitted to the Italian network of Intensive Cardiac Care Units (ICCU). Between 
2001 and 2014, more than 28,000 patients were enrolled in 5 subsequent Registries, each of 
them involving a representative sample of the country ICCU network. Over the years, the 
invasive approach to acute coronary syndromes has steadily increased, with improved 
outcome in all patient categories, irrespective of age and sex,
2,3
 cardiogenic shock status,
4
 
presence of atrial fibrillation
5
 or concomitant vascular disease.
6
 The present analysis is aimed 
to investigate the evolution of patient characteristics, treatment and outcome of patients with 
diabetes admitted to ICCUs for an acute coronary syndrome. 
 
METHODS 
Study design and population  
The patients included  in the present analysis were enrolled in 5 consecutive nationwide 
prospective surveys on acute coronary syndromes ICCU admissions coordinated by the 
ANMCO between 2001 and 2014: Blitz-1 in 2001,
7
 IN-ACS Outcome (Italian Network 
on Acute Coronary Syndromes Outcome) in 2006–2007,8 Blitz-4 in 2009-2010,9 
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MANTRA (Management of patients with acute coronary syndromes in the real world 
practice in Italy: an outcome research study focused on the use of ANTithRombotic 
Agents) in 2009–2010,10 and EYESHOT (EmploYEd antithrombotic therapies in 
patients with acute coronary Syndromes Hospitalized in iTalian cardiac care units) in 
2013-2014.
11
 All studies enrolled across the acute coronary syndromes spectrum, 
including both ST-Elevation myocardial infarction and Non-ST-Elevation acute coronary 
syndromes patients. For the present analysis patients were categorized according to 
diabetes status.  
The principles and procedures used for each registry have been described previously.
7-11 
The ANMCO Research Centre (Centro Studi ANMCO) was appointed to coordinate the 
project, to provide support to the committees, local coordinators and participating 
centres, and to oversee the methodological aspects of the surveys. All databases were set 
up at the ANMCO Research Centre, according to the requirements defined by the 
appointed Executive Committee. Informed consent was obtained from all patients. Local 
Institutional Review Boards approved the protocols. 
 
Definitions 
Data on previous medical history and medications ongoing at admission, baseline 
characteristics, cardiac procedures, use of medications during hospitalization and at 
hospital discharge, and in-hospital major clinical events, were recorded. The definitions 
of inclusion criteria and outcome events were consistent throughout the surveys. 
The presence of known diabetes was defined by a previous physician’s diagnosis 
reported by the patients, or information from their medical records when available. De 
novo diabetes was defined, according to standard criteria, as absence of a prior diagnosis 
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of diabetes but a fasting plasma venous glucose >126 mg/dL or random plasma venous 
glucose >200 mg/dL during ICCU stay.  
Body mass index (BMI) was calculated by dividing patients’ weight in kilograms by 
their height in meters squared. Patients were considered to have hypertension if their 
blood pressure was ≥140/90 mmHg or if they were on anti-hypertensive treatment. 
Venous blood samples were drawn in the morning after an overnight fast. Serum 
creatinine, glucose, and other biochemical blood measurements were determined using 
standard laboratory procedures. The glomerular filtration rate (e-GFR) was estimated by 
the four-variable Modification of Diet in Renal Disease (MDRD) study equation.
12
 
Presence of chronic kidney disease was defined as an e-GFR value <60 mL/min/1.73 m
2
. 
Conventional trans-thoracic echocardiography or left ventriculography were used to 
calculate ejection fraction according to international standard criteria. An invasive 
approach was defined as use of coronary angiography during ICCU stay followed, 
whenever clinically indicated and technically feasible, by revascularization either by 
percutaneous coronary intervention or bypass surgery. For the Blitz-4 study, angioplasty 
and bypass surgery data were not available for patients transferred from Centers without 
coronary interventional facilities: therefore, revascularization data were not used for this 
study.  
 
Study outcomes 
In-hospital all-cause mortality was the primary outcome of the present analysis. The 
main secondary outcome of interest was cardiogenic shock. In all of the study protocols, 
cardiogenic shock was defined as systolic blood pressure (BP) of <90 mmHg lasting more 
than 60 min, nonresponsive to water challenge or requiring the administration of inotropic 
drugs in order to obtain a systolic BP of >90 mmHg, with clinical signs of peripheral 
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hypoperfusion such as sensorial obnubilation, low urine output (<30 ml/h), cold sweat or 
cyanosis.
4 
All study outcomes were ascertained in the whole cohort and are herein shown 
separately for patients with and without diabetes.  
 
Statistical analysis 
Categorical variables are presented as number and percentages, and continuous variables 
as means and standard deviations (SD), except for the duration of hospitalization and the 
length of ICCU stay, which are reported as median and inter-quartile range (IQR). 
Categorical variables were compared by the 2 test, while continuous variables by the t-
test, if normally distributed, or the Mann-Withney U-test, if not. Temporal trends were 
tested using the Cochran-Armitage test for binary variables and the Kendall Tau rank 
correlation coefficient with the Jonckheere-Terpstra test for continuous variables. A 
multivariable analysis (logistic model) was performed to evaluate the association 
between diabetes and cardiogenic shock, over time, adjusting for study cohort (year, 
2001 as reference), diabetes, and the following variables: gender, prior myocardial 
infarction, prior heart failure, Killip class at entry >1, acute coronary syndrome 
presentation (ST elevation vs Non ST elevation), and age, systolic blood pressure, heart 
rate, and length of hospital stay, as continuous. 
Furthermore, a multivariable analysis (logistic regression) was performed to evaluate the 
association between diabetes and in-hospital all-cause mortality over time, adjusting for 
study cohort (year, 2001 as reference), gender, age (continuous), (treated) hypertension, 
smoking, BMI (<25 as reference; ≥25; missing), chronic obstructive pulmonary disease, 
history of heart failure, prior stroke/transient ischemic attack, prior myocardial 
infarction, prior revascularization, peripheral vascular disease, eGFR at entry (<60; ≥60 
as reference; missing), acute coronary syndrome presentation (STE vs NSTE), and 
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systolic blood pressure (as continuous). In case of categorical variables, when more than 
two categories were present, dummy variables were introduced to define a reference 
group. As sensitivity analysis, the model on in-hospital all-cause mortality was 
performed separately in patients with ST elevation and Non ST elevation, further 
adjusting for coronary revascularization in ST elevation patients and coronarography 
during admission in patients with non ST elevation acute coronary syndrome.  The risk 
estimates are reported as Odds Ratio (OR) and 95% confidence interval (CI). All tests 
were 2-sided; a p value<0.05 was considered statistically significant. All analyses were 
conducted with SAS system software version 9.2 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
Patient characteristics 
The overall study cohort included 28,225 acute coronary syndrome patients, of which 
8,521 (30.2%) had diabetes. Most patients with diabetes had previously known disease 
(n=7,327; 86.0%). Over the years diabetes prevalence increased from 22.2% in 2001 to 
32.3% in 2014 (P for trend <0.0001), as shown in Figure 1. The identification of 
diabetes subtypes was not possible by study design, although the vast majority of cases 
had likely type-2 diabetes. As shown in Table 1, patients with diabetes were more often 
women and significantly older, as compared to those without diabetes. The diagnosis of 
diabetes was also accompanied by a higher prevalence of comorbidities (particularly 
chronic obstructive pulmonary disease and impaired kidney function at entry), as well as 
prior cardiovascular events (myocardial infarction, stroke) and revascularization 
procedures. Left ventricular ejection fraction was significantly lower in patients with 
diabetes.  As for the acute coronary syndrome presentation, the prevalence of non ST 
elevation acute coronary syndrome was higher in individuals with vs. without diabetes 
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(59.2 vs. 50.6%, P <0.0001). The prevalence of chronic kidney disease, as well as 
clinical history of coronary angioplasty or bypass surgery, increased over time in the 
whole cohort (Supplementary table 1), and in patients with and without diabates. 
 
Treatment strategies 
In the overall study cohort, coronary angiography was performed in 78.8% of patients 
with, as compared to 84.7% of those without diabetes (p<0.0001) (Supplementary 
Table 2). Percutaneous or surgical coronary revascularization was performed in 57.7% 
of patients with vs 63.9% of those without diabetes (p<0.0001), with angioplasty 
representing the majority of the revascularization procedures (92.9% in patients with 
diabetes vs 95.5%, in patients without diabetes, p<0.0001). Overall, patients with 
diabetes were more likely to be treated by medical-only therapy as compared to those 
without diabetes (42.3 vs. 36.1%, P <0.0001).  
As shown in Table 2, there was an increase over time in referral to coronary 
angiography, and a reduction in thrombolytic therapy in ST elevation myocardial 
infarction, both among patients with and without diabetes.  Few differences were found 
in cardiac specific medications in patients with or witout diabetes (Supplementary 
Table 2). 
 
Cardiogenic shock 
Overall, cardiogenic shock rates were 3-fold higher in patients with diabetes (7.8% vs. 2.8%, 
p<0.0001). Over the years (Figure 2), cardiogenic shock rates decreased significantly in 
patients without diabetes (p for trend=0.007) but remained unchanged in patients with 
diabetes (p for trend=0.74). At multivariable analysis, diabetes was an independent predictor 
of cardiogenic shock (OR 2.03, 95% C.I. 1.77-2.32, p<.0001) (Figure 3A).  
Journal Pre-proof
Downloaded for Anonymous User (n/a) at Regional Health Care and Social Agency Great Metropolitan Hospital Niguarda from ClinicalKey.com by Elsevier on August 28, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Jo
urn
al 
Pr
e-p
roo
f
Dauriz, Time Trends in ACS and Diabetes 10 
 
 10 
 
In-hospital mortality  
As shown in Table 3, patients with diabetes had significantly higher rates of in-hospital 
all-cause death (5.4% vs 2.5%, p <0.0001), and in-hospital complications (22.3% vs. 
10.8%, P <0.0001) as compared to those without diabetes. Notably, patients with 
diabetes displayed at least 2-fold higher mortality rates as compared to those without DM 
across all study years, despite a remarkable reduction of overall mortality in both patient 
subsets after the BLITZ-1 study in 2001. Case fatality of cardiogenic shock was similar 
in patients with or without diabetes (42.6% vs 43.1%, p=0.86) but, due to higher rates of 
cardiogenic shock among patients with diabetes, it accounted for 61.1% of overall 
mortality among patients with diabetes (283 out of 463 deaths), as compared to 48.0% 
among patients without diabetes (233 out of 485 deaths). Both the total (8 [5-11] vs.  7 
[5-9] days, P <0.0001) and ICCU-specific (4 [3-6] vs. 4 [2-5] days, P <0.0001) length of 
stay were longer in patients with vs. without diabetes.  
At multivariable analysis in the whole acute coronary syndrome population, DM was 
found to be an independent predictor of in-hospital all-cause mortality (OR 1.95; 95% CI 
1.69-2.26; p <0.0001) together with other established predictors (Figure 3B). The strong 
association between diabetes and in-hospital mortality remained even in the sensitivity 
analysis, stratifying for acute coronary syndrome presentation and further adjusting for 
coronary revascularization in patients with ST elevation (OR 2.04; 95% CI 1.69-2.45, 
p<0.0001) and coronary angiography on admission for patients with non ST elevation 
acute coronary syndrome (OR 1.72; 95% CI 1.35-2.20, p<0.0001). 
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DISCUSSION 
The present analysis provides an update of the epidemiology, management and outcome 
of patients with diabetes mellitus and acute coronary syndromes, based on a series of 
contemporary nationwide registries of consecutive ICCU admissions. The main findings 
are the following: 1. nearly 30% of acute coronary syndrome patients have diabetes (4% 
as de novo diagnosis), and this rate has been increasing over time; 2. as compared to 
patients without diabetes, those with diabetes are older, and have a higher prevalence of 
prior cardiovascular events and comorbidities; 3. After adjustment for prior cardiac 
events and comorbidities, patients with diabetes have twice the rate of cardiogenic shock, 
as compared to patients without diabetes, with the same case-fatality; 4. the rates of 
cardiogenic shock have decreased significantly among patients without diabetes, but not 
among those with diabetes; 5. the use of revascularization has significantly increased in 
all patients over the years, but both coronary angiography and angioplasty rates remained 
lower in patients with diabetes; 6. in-hospital mortality did decrease over time both in 
patients with and without diabetes, but remained two-fold higher among patients with 
diabetes; 7. after adjustment for multiple comorbidities and prior coronary 
revascularization, diabetes remains among the independent predictors of mortality.  
This data is consistent with a systematic review and metanalysis of 110 studies, 
including randomized trials and registries,
1
 but provide new epidemiological insight, 
since they derive from a representative nationwide sample of acute coronary syndrome 
patients in a period of transition from a predominantly medical to a largely interventional 
treatment of acute coronary syndromes. According to the present data, the rates of 
patients with diabetes are much higher in clinical practice than in randomized clinical 
trials that form the evidence basis of practice guidelines.
13
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Several studies have described how the management of patients with acute coronary 
syndromes and diabetes has improved with early reperfusion and revascularization.
13,14
 
However, as shown by a recent metaregression analysis, the incremental mortality risk 
associated with diabetes among acute coronary syndrome patients has remained constant 
over a long period of time (1970 to 2011).
1
 Our results are in line with this data, also 
showing a temporal decrease in the overall risk of in-hospital mortality and confirming 
the independent and strong association between diabetes and mortality across  the 
spectrum of acute coronary syndromes.  
The present data may help discriminating the causes for this persistingly higher mortality 
among acute coronary syndrome patients with diabetes. Patients with diabetes are older, 
as compared to patients without diabetes, most probably reflecting the epidemiological 
predominance of maturity-onset type 2 diabetes.
15,16
 However, patients with diabetes 
present more often with prior myocardial infarction and revascularization procedures, 
reflecting the premature progression of coronary disease caused by the disease. 
Prevalence of chronic kidney dysfunction has also been found to be 3-fold higher among 
patients with diabetes, and increasing over time, reflecting more extensive vascular 
disease. For all these reasons, not surprisingly the rates of coronary revascularization, 
though increased overtime in the overall population, remained significantly lower in 
patients with diabetes.  
This combination of prior coronary events, particularly myocardial infarction, and also 
lower revascularization rates in the acute phase, is the most likely explanation of the 
higher rate of cardiogenic shock among patients with diabetes. Diabetes is largely over-
represented in the cardiogenic shock population: whereas in the overall acute coronary 
syndrome population patients with diabetes increased from 22% in 2001 to 32% in 2014, 
they increased from 35% to 56% in the cardiogenic shock population,
 
a rate even higher 
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in clinical practice than that enrolled in the most recent Culprit Shock randomized trial of 
acute coronary syndrome patients with multivessel coronary disease.
17
  Whether this  
most severe presentation of acute coronary syndromes among patients with diabetes is to 
be attributed to pre-existing myocardial damage, to worse myocardial metabolism under 
ischemic conditions,
18,19
 or both, remains matter of further investigation. After the acute 
coronary syndrome event, markers of myocardial dysfunction have been shown to be by 
far the most important predictors of mortality among patients with diabetes.
20
 Over the 
present study period, the case fatality of cardiogenic shock decreased from 68% in 2001 
to 38% in 2014, both in patients with and in those without diabetes. Therefore, at least 
part of the persistingly higher mortality risk associated with diabetes in the setting of 
acute myocardial infarction should be attributed to higher rates of cardiogenic shock, 
which were reduced significantly over time in patients without diabetes, but did not 
change among those with diabetes. In the present analysis, cardiogenic shock has been 
found responsible for 61% of mortality in patients with diabetes, as compared to 48% 
among those without diabetes. 
These conclusions may have important implications for clinical practice. According to 
the present data, acute care of acute coronary syndromes has provided consistent benefit 
both in patients without and with diabetes. More effort should be devoted to preventing 
the first acute coronary syndrome event through aggressive risk factor control,
21
 as well 
as ischemic recurrencies and left ventricle deterioration by a more extensive integration 
of recent pharmacological advances in antidiabetic therapy.
22
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FIGURE LEGENDS 
 
Figure 1 – Nationwide prevalence of diabetes mellitus (DM) in 28,225 patients 
hospitalized for Acute Coronary Syndrome in the italian Intensive Cardiac Care 
Units over 2001-2014. 
The picture shows the overall study-specific prevalence of diabetes mellitus stratified as 
to whether the diagnosis was already present prior to hospital admission (known 
diabetes) or it occurred during hospitalization (de novo diabetes), as a combination of 
data from five consecutive nationwide prospective surveys conducted between 2001 and 
2014 and comprising 28,225 patients. De novo diabetes evaluated excluding Blitz-1 
study (data on glycemia not available). 
 
Figure 2 – Cardiogenic shock rates in patients with or without diabetes mellitus in 
the 5 ICCU registries.  
Bars are percentages of patients with or without diabetes. P-value for comparison within 
each study: *p=0.0002; **p<0.0001. 
 
Figure 3A – Independent predictors of cardiogenic shock at logistic regression 
analysis. 
The predictors are ordered according to 2 value. Per cent predictive information is 
calculated as the proportion of the individual 2 compared to the sum of all 2. 
a
Analysed as continuous variable (the reported OR is for 1-year increase in age, 1mmHg 
increase in blood pressure, 1 beat per minute increase in heart rate). 
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Figure 3B– Independent predictors of all-cause in-hospital mortality at logistic 
regression analysis. 
The predictors are ordered according to 2 value. Per cent predictive information is 
calculated as the proportion of the individual 2 compared to the sum of all 2. 
a
Analysed as continuous variable (the reported OR is for 1-year increase in age, 1mmHg 
increase in blood pressure, 1 beat per minute increase in heart rate). 
 
 
Clinical significance points 
1. Mortality in Acute Coronary Syndromes has improved with early invasive treatment. 
Whether this is true in patients with diabetes is unclear.   
2. Rates of early revascularization have increased both in patients with and in those 
without diabetes.  
3. Cardiogenic shock rates decreased only in patients without diabetes.  
4. Mortality decreased more consistently in patients without diabetes.   
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Table 1 - Main demographic, clinical and biochemical characteristics of 28,225 patients 
admitted to the ICCUs. 
 
 
ALL 
(N=28,225) 
Patients 
WITH 
diabetes 
(N=8,521) 
Patients 
WITHOUT 
diabetes 
(N=19,704) 
P-value 
Male, n (%) 19,688 (69.8) 5,429 (63.7) 14,259 (72.4) <0.0001 
Age, years, mean±SD 68±13 71±11 66 ±13 <0.0001 
BMI, kg/m
2 #,
 mean±SD 26.9 ±4.2 27.7±4.5 26.5±4.0 <0.0001 
Systolic blood pressure, mmHg, 
mean±SD 
137±27 139±28 136±26 <0.0001 
Diastolic blood pressure, mmHg, 
mean±SD 
79±15 78±15 80±15 <0.0001 
Heart rate, bpm, mean±SD 79±19 83±21 77±18 <0.0001 
Diabetes, n, % 8,521 (30.2%) 8,521 (100.0) -  
- De novo
§
 1,194 (4.5%) 1,194 (14.8) -  
- Known 7,327 (25.9%) 7,327 (85.9) -  
Diabetes medications^, n (%)     
- Insulin (only) - 1,656 (22.6) - - 
- Oral hypoglycemic drugs 
(only) 
- 4,082 (55.7) - - 
- Both Insulin and oral 
hypoglycemic drugs 
- 167 (2.3) - - 
- Diet - 1,422 (19.4) - - 
Plasma glucose at CCU admission, 
mg/dL
*
, mean±SD
 
150±73 216±94 120±27 <0.0001 
Current smoking, n (%)  8,917 (31.6) 1,865 (21.9) 7,052 (35.8) <0.0001 
Hypertension on treatment, n (%) 16,307 (57.8) 5,997 (70.4) 10,310 (52.3) <0.0001 
Total cholesterol, mg/dL 
**
, 
mean±SD 
190±45 180±45 194±44 <0.0001 
Lipid-lowering medications, n (%) 
***
 
5,818 (22.7) 2,443 (31.7) 3,375 (18.8) <0.0001 
Cardiovascular medications, n (%) 
 
    
- ACE-I or ARBs 
***
 10,630 (41.4) 4,036 (52.4) 6,594 (36.7) <0.0001 
- Betablockers 
***
 5,874 (22.9) 2,166 (28.1) 3,708 (20.6) <0.0001 
- Antiplatelets or 
Anticoagulants° 
10,930 (38.8) 4,477 (52.6) 6,453 (32.8) <0.0001 
Creatinine, mg/dL 
$
, mean±SD 1.1±0.8 1.3±1.0 1.1±0.7 <0.0001 
e-GFRMDRD, mL/min/1.73 m
2 $
, 
mean±SD 
76±29 68.3±29 80±28 <0.0001 
e-GFRMDRD <60 mL/min/1.73 m
2
, n 
(%) 
6,365 (26.2) 2,959 (39.2) 3,406 (20.4) <0.0001 
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ALL 
(N=28,225) 
Patients 
WITH 
diabetes 
(N=8,521) 
Patients 
WITHOUT 
diabetes 
(N=19,704) 
P-value 
LVEF, % 
$$
, mean±SD 50±11 47.1±11.1 51±10 <0.0001 
LVEF    <0.0001 
≤ 30%, n (%) 1,657 (6.6) 795 (10.3) 862 (4.9)  
31-44%, n (%) 4,826 (19.1) 1,834 (23.7) 2,992 (17.1)  
≥ 45%, n(%) 18,772 (74.3) 5,097 (66.0) 13,675 (78.0)  
COPD, n (%) 2,146 (7.7) 841 (10.0) 1,305 (6.7) <0.0001 
CKD, n (%) 2,383 (8.4) 1,250 (14.7) 1,133 (5.8) <0.0001 
PVD, n (%) 2,982 (10.6) 1,410 (16.6) 1,572 (8.0) <0.0001 
Family history of CVD
$$$
, n (%)
 
4,087 (27.1) 1,024 (24.2) 3,063 (28.3) <0.0001 
Prior CABG, n (%) 1,716 (6.1) 842 (9.9) 874 (4.4) <0.0001 
Prior PCI, n (%) 3,824 (13.6) 1,518 (17.8) 2,306 (11.7) <0.0001 
Prior MI, n (%) 4,804 (17.0) 1,949 (22.9) 2,855 (14.5) <0.0001 
Prior Stroke/TIA, n (%) 1,649 (5.8) 736 (8.6) 913 (4.6) <0.0001 
ACS etiology, n (%)    <0.0001 
  (NSTE-ACS), n (%) 15,015 (53.2) 5,045 (59.2) 9970 (50.6)  
  (STEMI), n (%) 13,210 (46.80) 3,476 (40.8) 9,734 (49.4)  
 
# 
available for 27163 patients. 
§
De novo diabetes was defined as absence of a prior diagnosis 
of diabetes but a fasting or random plasma venous glucose >200 mg/dL; evaluated among 
26266 patients, 8087 with diabetes mellitus (Blitz-1 excluded because glycemia not 
available). ^Data available in 7,327 patients with history of diabetes. 
* 
available for 24196 
patients. 
** 
available for 10896 patients. 
*** 
available for 25689 patients. ° available for 
28197 patients. 
$ 
available for 24290 patients. 
$$ 
at entry/during hospital stay; available for 
25255 patients. 
$$$ 
available for 15069 patients. 
 
 
ACE-I=angiotensin-converting-enzyme inhibitors; ARB=angiotensin receptor blocker; 
BMI=body mass index; CABG=coronary artery bypass; CCU=coronary care unit; 
COPD=chronic obstructive pulmonary disease; CKD=chronic kidney disease; CVD; e-
GFRMDRD=glomerular filtration rate estimated according to the Modification of Diet in Renal 
Disease (MDRD) study equation; ICCU=intensive cardiac care unit; LVEF=left ventricular 
ejection fraction; MI=myocardial infarction; NSTE-ACS= Non-ST-Segment Elevation acute 
coronary syndrome; PCI=percutaneous coronary intervention; PVD=peripheral vascular 
disease; SD=standard deviation; STEMI=ST-Elevation Myocardial Infarction; TIA=transient 
ischemic attack.  
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Table 2. Treatment stratified by study in patients with or without diabetes. 
 
STEMI treatment 
in patients WITH 
diabetes 
ALL 
(N=3,476) 
BLITZ-1 
(N=293) 
IN-ACS 
OUTCOME 
(N=608) 
BLITZ-4 
(N=1,589) 
MANTRA 
(N=719) 
EYESHOT 
(N=267) 
P trend 
Coronary angiography 
% 
2,928 
(84.2) 
115 (39.3) 494 (81.3) 
1,447 
(91.1) 
618 (86.0) 254 (95.1) <0.0001 
Medical only, %  918 (26.4) 132 (45.1) 180 (29.6) 363 (22.8) 200 (27.8) 43 (16.1)  
Primary PCI, % 
1,942 
(55.9) 
24 (8.2) 282 (46.4) 
1035 
(65.1) 
397 (55.2) 204 (76.4) <0.0001 
Thrombolysis, %  616 (17.7) 137 (46.7) 146 (24.0) 191 (12.1) 122 (17.0) 20 (7.5) <0.0001 
PCI# 
1,241 
(65.8) 
54 (18.4) 421 (69.2) - 539 (75.0) 227 (85.0) <0.0001 
CABG# 46 (2.4) 3 (1.0) 19 (3.1)  20 (2.8) 4 (1.5) 0.87 
STEMI treatment 
in patients WITHOUT 
diabetes 
ALL 
(N=9734) 
BLITZ-1 
(N=1,081) 
IN-ACS 
OUTCOME 
(N=1,673) 
BLITZ-4 
(N=4,067) 
MANTRA 
(N=2,139) 
EYESHOT 
(N=774) 
P trend 
Coronary 
Angiography, % 
8539 
(87.7) 
526 (48.7) 1,460 (87.3) 
3,886 
(95.5) 
1,924 
(90.0) 
743 (96.0) <0.0001 
Medical only, %  
1915 
(19.7) 
400 (37.0) 393 (23.5) 638 (15.7) 377 (17.6) 107 (13.8)  
Primary PCI, % 
5,976 
(61.4) 
166 (15.4) 837 (50.0) 
2,941 
(72.3) 
1,424 
(66.6) 
608 (78.6) <0.0001 
Thrombolysis, %  
1,843 
(18.9) 
515 (47.6) 443 (26.5) 488 (12.0) 338 (15.8) 59 (7.6) <0.0001 
PCI* 
4025 
(71.0) 
345 (31.9) 1,271 (76.0) - 
1,735 
(81.1) 
674 (87.1) <0.0001 
CABG* 91 (1.6) 11 (1.0) 37 (2.2)  35 (1.6) 8 (1.0) 0.67 
NSTE-ACS 
treatment, in patients 
WITH Diabetes 
ALL 
(N=5045) 
BLITZ-1 
(N=141) 
IN-ACS 
OUTCOME 
(N=1,116) 
BLITZ-4 
(N=2,055) 
MANTRA 
(N=1,182) 
EYESHOT 
(N=551) 
P trend 
Coronary angiography, 
% 
3,789 
(75.1) 
50 (35.5) 808 (72.4) 
1,626 
(79.1) 
877 (74.2) 428 (77.7) <0.0001 
PCI, %° 
1,376 
(46.0) 
20 (14.2) 507 (45.4) - 580 (49.1) 269 (48.8) <0.0001 
CABG, % ° 173 (5.8) 3 (2.1) 78 (7.0) - 76 (6.4) 16 (2.9) 009 
NSTE-ACS 
treatment, in patients 
WITHOUT Diabetes 
ALL 
(N=9,970) 
BLITZ-1 
(N=444) 
IN-ACS 
OUTCOME 
(N=2,497) 
BLITZ-4 
(N=3,731) 
MANTRA 
(N=2,354) 
EYESHOT 
(N=944) 
P trend 
Coronary angiography, 
% 
8,147 
(81.7) 
200 (45.1) 1,945 (77.9) 
3,299 
(88.4) 
1,891 
(80.3) 
812 (86.0) <0.0001 
PCI, %** 
3,236 
(51.9) 
70 (15.8) 1,264 (50.6) - 
1,351 
(57.4) 
551 (58.4) <0.0001 
CABG, %** 286 (4.6) 10 (2.3) 131 (5.3) - 122 (5.2) 23 (2.4) 0.29 
 
#
Data available on 1,887 patients. *Data available on 5,667 patients. °Data available on 
2,990 patients. 
**
Data available on 6,239 patients. 
ACS: Acute coronary syndrome; PCI: percutaneous coronary intervention; CABG: coronary 
artery bypass.  
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Table 3 – In-hospital outcomes in patients with and without diabetes, stratified by 
study. 
 
ALL 
(N=28,225) 
BLITZ-1 
(N=1,959) 
IN-ACS 
OUTCOME 
(N=5,894) 
BLITZ-4 
(N=11,442) 
MANTRA 
(N=6,394) 
EYESHOT 
(N=2536) 
Outcome
s 
D 
(n=852
1) 
No-D 
(n=1970
4) 
P-
value 
D 
(n=43
4) 
No-D 
(n=1,52
5) 
D 
(n=1,72
4) 
No-D 
(n=4,17
0) 
D 
(n=3,64
4) 
No-D 
(n=7,79
8) 
D 
(n=1,90
1) 
No-D 
(n=4,49
3) 
D 
(n=81
8) 
No-D 
(n=1,71
8) 
All-cause 
death (n, 
%) 
463 
(5.43) 
485 
(2.46) 
<0.00
01 
49 
(11.3) 
95 
(6.2)** 
79 (4.6) 
87 
(2.1)* 
200 
(5.5) 
153 
(2.0)* 
98 (5.2) 
111 
(2.5*) 
37 
(4.5) 
39 
(2.3)** 
Cardioge
nic shock 
(n, %) 
665 
(7.80) 
541 
(2.75) 
<0.00
01 
46 
(10.6) 
85 
(5.7)** 
99 (5.7) 
87 
(2.1)* 
332 
(9.1) 
212 
(2.7)* 
121 
(6.4) 
105 
(2.3)* 
67 
(8.2) 
52 
(3.1)* 
Complica
ted 
hospital 
course
*
 
(n, %) 
1,901 
(22.3) 
 
2,134 
(10.8) 
 
<0.00
01 
 
149 
(34.3) 
 
301 
(19.7)* 
 
287 
(16.7) 
 
392 
(9.4)* 
 
908 
(24.9) 
 
859 
(11.0)* 
 
363 
(19.1) 
 
409 
(9.1)* 
 
194 
(23.7) 
 
173 
(10.1)* 
 
Length of 
hospital 
stay 
(days) 
Median 
[IQR] 
8 [5-
11] 
7 [5-9] 
<0.00
01 
10 [8-
14] 
9 [7-
12]** 
7 [5-10] 7 [5-9]* 7 [5-10] 7 [5-9]* 7 [6-10] 7 [5-9]* 
8 [6-
11] 
7 [5-9]* 
Length of 
ICCU 
stay 
(days)
# 
Median 
[IQR] 
4 [3-6] 4 [2-5] 
<0.00
01 
4 [3-
6] 
4 [3-5]* 3 [2-5] 3 [2-4]* 5 [3-7] 4 [3-6]* 3 [2-5] 3 [2-5]* 
4 [2-
6] 
3 [2-5]* 
 
* p<0.0001 
** p<0.001 
#
available for 28,222 patients 
 
*
Including at least one of the followings: heart failure, pulmonary oedema, cardiogenic 
shock, re-infarction (in ICCU), stroke/, major bleeding, mechanical or disventilatory 
complications. 
 
D=diabetes; No-D=no diabetes; ICCU=Intensive coronary care unit 
low molecular weight heparin; UFH, un-fractioned heparin; GPI, glycoprotein inhibitors; 
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